Literature DB >> 29763620

Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential.

Michael J Lukey1, William P Katt1, Richard A Cerione2.   

Abstract

Identifying contexts in which cancer cells become addicted to specific nutrients is critical for developing targeted metabolic therapies. In this issue of Cancer Cell, Momcilovic et al. report that suppressed glycolysis following mTOR inhibition is countered by adaptive glutamine catabolism in lung squamous cell carcinoma, sensitizing tumors to glutaminase inhibition.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29763620      PMCID： PMC9062989          DOI： 10.1016/j.ccell.2018.04.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Targeted therapy for squamous cell lung cancer.

Authors:  Rachel G Liao; Hideo Watanabe; Matthew Meyerson; Peter S Hammerman
Journal:  Lung Cancer Manag       Date:  2012-12

2.  Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer.

Authors:  Shawn M Davidson; Thales Papagiannakopoulos; Benjamin A Olenchock; Julia E Heyman; Mark A Keibler; Alba Luengo; Matthew R Bauer; Abhishek K Jha; James P O'Brien; Kerry A Pierce; Dan Y Gui; Lucas B Sullivan; Thomas M Wasylenko; Lakshmipriya Subbaraj; Christopher R Chin; Gregory Stephanopolous; Bryan T Mott; Tyler Jacks; Clary B Clish; Matthew G Vander Heiden
Journal:  Cell Metab       Date:  2016-02-04       Impact factor: 27.287

3.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

4.  c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.

Authors:  Ping Gao; Irina Tchernyshyov; Tsung-Cheng Chang; Yun-Sil Lee; Kayoko Kita; Takafumi Ochi; Karen I Zeller; Angelo M De Marzo; Jennifer E Van Eyk; Joshua T Mendell; Chi V Dang
Journal:  Nature       Date:  2009-02-15       Impact factor: 49.962

5.  The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.

Authors:  Michael J Lukey; Kai Su Greene; Jon W Erickson; Kristin F Wilson; Richard A Cerione
Journal:  Nat Commun       Date:  2016-04-18       Impact factor: 14.919

6.  Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition.

Authors:  Alexander Muir; Laura V Danai; Dan Y Gui; Chiara Y Waingarten; Caroline A Lewis; Matthew G Vander Heiden
Journal:  Elife       Date:  2017-08-15       Impact factor: 8.140

7.  Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.

Authors:  Milica Momcilovic; Robert McMickle; Evan Abt; Atsuko Seki; Sarah A Simko; Clara Magyar; David B Stout; Michael C Fishbein; Tonya C Walser; Steven M Dubinett; David B Shackelford
Journal:  Cancer Res       Date:  2015-11-15       Impact factor: 13.312

8.  The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.

Authors:  Milica Momcilovic; Sean T Bailey; Jason T Lee; Michael C Fishbein; Daniel Braas; James Go; Thomas G Graeber; Francesco Parlati; Susan Demo; Rui Li; Tonya C Walser; Michael Gricowski; Robert Shuman; Julio Ibarra; Deborah Fridman; Michael E Phelps; Karam Badran; Maie St John; Nicholas M Bernthal; Noah Federman; Jane Yanagawa; Steven M Dubinett; Saman Sadeghi; Heather R Christofk; David B Shackelford
Journal:  Cancer Cell       Date:  2018-05-14       Impact factor: 38.585

9.  Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Authors:  Rodrigo Romero; Volkan I Sayin; Shawn M Davidson; Matthew R Bauer; Simranjit X Singh; Sarah E LeBoeuf; Triantafyllia R Karakousi; Donald C Ellis; Arjun Bhutkar; Francisco J Sánchez-Rivera; Lakshmipriya Subbaraj; Britney Martinez; Roderick T Bronson; Justin R Prigge; Edward E Schmidt; Craig J Thomas; Chandra Goparaju; Angela Davies; Igor Dolgalev; Adriana Heguy; Viola Allaj; John T Poirier; Andre L Moreira; Charles M Rudin; Harvey I Pass; Matthew G Vander Heiden; Tyler Jacks; Thales Papagiannakopoulos
Journal:  Nat Med       Date:  2017-10-02       Impact factor: 53.440

10.  Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer.

Authors:  Volkan I Sayin; Sarah E LeBoeuf; Simranjit X Singh; Shawn M Davidson; Douglas Biancur; Betul S Guzelhan; Samantha W Alvarez; Warren L Wu; Triantafyllia R Karakousi; Anastasia Maria Zavitsanou; Julian Ubriaco; Alexander Muir; Dimitris Karagiannis; Patrick J Morris; Craig J Thomas; Richard Possemato; Matthew G Vander Heiden; Thales Papagiannakopoulos
Journal:  Elife       Date:  2017-10-02       Impact factor: 8.140
  10 in total
  7 in total

Review 1.  New insights into extracellular vesicle biogenesis and function.

Authors:  Arash Latifkar; Yun Ha Hur; Julio C Sanchez; Richard A Cerione; Marc A Antonyak
Journal:  J Cell Sci       Date:  2019-07-01       Impact factor: 5.285

2.  N6-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming.

Authors:  Kun Zhang; Tao Zhang; Yuhan Yang; Wenling Tu; Hongbin Huang; Yujun Wang; Yuzhuo Chen; Kejian Pan; Zhuojia Chen
Journal:  Theranostics       Date:  2022-06-13       Impact factor: 11.600

3.  Glutamine deprivation alters the origin and function of cancer cell exosomes.

Authors:  Shih-Jung Fan; Benjamin Kroeger; Pauline P Marie; Esther M Bridges; John D Mason; Kristie McCormick; Christos E Zois; Helen Sheldon; Nasullah Khalid Alham; Errin Johnson; Matthew Ellis; Maria Irina Stefana; Cláudia C Mendes; Stephen Mark Wainwright; Christopher Cunningham; Freddie C Hamdy; John F Morris; Adrian L Harris; Clive Wilson; Deborah Ci Goberdhan
Journal:  EMBO J       Date:  2020-07-28       Impact factor: 14.012

4.  miR-16-5p/PDK4-Mediated Metabolic Reprogramming Is Involved in Chemoresistance of Cervical Cancer.

Authors:  Zhao Zhao; Mei Ji; Qianqing Wang; Nannan He; Yue Li
Journal:  Mol Ther Oncolytics       Date:  2020-05-23       Impact factor: 7.200

5.  IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells.

Authors:  Qing He; Peng Hao; Gang He; Hantao Mai; Wenzhou Liu; Weiqiong Zhang; Kelin Zhang; Guifang Zhong; Ruilian Guo; Changzhi Yu; Yang Li; Chipiu Wong; Qian Chen; Yantao Chen
Journal:  J Transl Med       Date:  2022-08-02       Impact factor: 8.440

6.  miR-137/ERRα axis mediates chemoresistance of nasopharyngeal carcinoma cells.

Authors:  Fei Liu; Chunsheng Gao; Wenjuan Wang; Jing Hu; Zuofeng Huang; Meng Liang; Shuo Li
Journal:  J Cell Commun Signal       Date:  2021-07-01       Impact factor: 5.782

7.  N6-methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming.

Authors:  Zhuojia Chen; Long Wu; Jiawang Zhou; Xinyao Lin; Yanxi Peng; Lichen Ge; Cheng-Ming Chiang; Hui Huang; Hongsheng Wang; Weiling He
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.